BRPI0907228A2 - Compostos de tienopiridazina, suas preparações, composições farmacêuticas e usos - Google Patents

Compostos de tienopiridazina, suas preparações, composições farmacêuticas e usos

Info

Publication number
BRPI0907228A2
BRPI0907228A2 BRPI0907228-4A BRPI0907228A BRPI0907228A2 BR PI0907228 A2 BRPI0907228 A2 BR PI0907228A2 BR PI0907228 A BRPI0907228 A BR PI0907228A BR PI0907228 A2 BRPI0907228 A2 BR PI0907228A2
Authority
BR
Brazil
Prior art keywords
preparations
pharmaceutical compositions
thienopyridazine
compounds
thienopyridazine compounds
Prior art date
Application number
BRPI0907228-4A
Other languages
English (en)
Inventor
Zhanggui Wu
Original Assignee
Zhe Jiang Medicine Co Ltd Xinchang Pharmaceutical Factory
Zhanggui Wu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zhe Jiang Medicine Co Ltd Xinchang Pharmaceutical Factory, Zhanggui Wu filed Critical Zhe Jiang Medicine Co Ltd Xinchang Pharmaceutical Factory
Publication of BRPI0907228A2 publication Critical patent/BRPI0907228A2/pt
Publication of BRPI0907228B1 publication Critical patent/BRPI0907228B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BRPI0907228-4A 2008-01-08 2009-01-07 Compostos de tienopiridazina, suas preparações, composições farmacêuticas e usos BRPI0907228B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN200810000936.9 2008-01-08
CN200810000936 2008-01-08
CN2009100003371A CN101481380B (zh) 2008-01-08 2009-01-06 噻吩并哒嗪类化合物及其制备方法、药物组合物及其用途
CN200910000337.1 2009-01-06
PCT/CN2009/000021 WO2009092278A1 (zh) 2008-01-08 2009-01-07 噻吩并哒嗪类化合物及其制备方法、药物组合物及其用途

Publications (2)

Publication Number Publication Date
BRPI0907228A2 true BRPI0907228A2 (pt) 2015-07-14
BRPI0907228B1 BRPI0907228B1 (pt) 2021-08-03

Family

ID=40878690

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0907228-4A BRPI0907228B1 (pt) 2008-01-08 2009-01-07 Compostos de tienopiridazina, suas preparações, composições farmacêuticas e usos

Country Status (11)

Country Link
US (3) US8318740B2 (pt)
EP (1) EP2241569B1 (pt)
JP (1) JP5456694B2 (pt)
KR (1) KR101512530B1 (pt)
CN (1) CN101481380B (pt)
AU (1) AU2009207968B2 (pt)
BR (1) BRPI0907228B1 (pt)
CA (1) CA2711629C (pt)
MX (1) MX2010007502A (pt)
RU (1) RU2494103C2 (pt)
WO (1) WO2009092278A1 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2012003286A (es) 2009-09-18 2012-06-19 Zhanggui Wu Nuevos compuestos y su uso terapeutico para inhibicion de proteina cinasa.
AU2014262636A1 (en) 2013-05-10 2015-11-26 Gilead Apollo, Llc ACC inhibitors and uses thereof
EA201591962A1 (ru) 2013-05-10 2016-06-30 Нимбус Аполло, Инк. Ингибиторы акк и их применение
EP2994128B1 (en) * 2013-05-10 2019-01-30 Gilead Apollo, LLC Acc inhibitors and uses thereof
AU2014262638A1 (en) 2013-05-10 2015-11-26 Gilead Apollo, Llc ACC inhibitors and uses thereof
EP3483167A1 (en) * 2013-06-26 2019-05-15 AbbVie Inc. Primary carboxamides as btk inhibitors
CN103288614B (zh) * 2013-06-27 2014-09-17 中国科学院昆明植物研究所 具有抗肿瘤活性的间苯三酚类化合物及其药物组合物
AU2014293013A1 (en) 2013-07-26 2016-03-17 Race Oncology Ltd. Combinatorial methods to improve the therapeutic benefit of bisantrene
CN103694217A (zh) * 2013-12-20 2014-04-02 华东师范大学 一种2,4-二取代噻吩衍生物及其制备方法和应用
US20240009190A1 (en) * 2020-01-07 2024-01-11 Shanghai Huayu Biotechnology Co., Ltd. Combination cancer therapy using chk inhibitor
CN115605484A (zh) * 2020-04-17 2023-01-13 浙江医药股份有限公司新昌制药厂（Cn） 一种噻吩并哒嗪类化合物的晶型及其制备方法和应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR025752A1 (es) 1999-09-28 2002-12-11 Bayer Corp Piridinas y piridacinas sustituidas con actividad de inhibicion de angiogenesis
ES2314443T3 (es) * 2003-08-15 2009-03-16 Astrazeneca Ab Tiofenos sustituidos y sus usos.
JP2007517843A (ja) * 2004-01-05 2007-07-05 アストラゼネカ アクチボラグ Ｃｈｋ１阻害剤であるチオフェン誘導体
AU2005238178A1 (en) * 2004-05-04 2005-11-10 F. Hoffmann-La Roche Ag Thienopyridazines as IKK inhibitors
BRPI0608659A2 (pt) * 2005-04-06 2010-11-30 Astrazeneca Ab composto, métodos para limitar a proliferação celular, de tratamento de um ser humano ou animal sofrendo de uma doença, e de tratamento de profilaxia do cáncer, para tratar cáncer, de tratamento de infecções associadas com cáncer, e de profilaxia de infecções associadas com cáncer, composição farmacêutica, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, métodos para inibir chk1 cinase, e um pak cinase, e para limitar a tumorigênese em um ser humano ou animal, e, processo para a preparação de um composto ou um sal farmaceuticamente aceitável do mesmo
EP2038289A2 (en) * 2006-04-21 2009-03-25 Amgen Inc. Thieno-[2,3-d]pyrimidine and thieno-pyridazine compounds and methods of use
US7851622B2 (en) * 2007-04-25 2010-12-14 Bristol-Myers Squibb Company Non-basic melanin concentrating hormone receptor-1 antagonists
WO2009003911A1 (en) * 2007-06-29 2009-01-08 4Sc Ag Thiophene-imidazopyridines

Also Published As

Publication number Publication date
CN101481380A (zh) 2009-07-15
KR101512530B1 (ko) 2015-04-15
US20090275585A1 (en) 2009-11-05
WO2009092278A8 (zh) 2010-07-22
EP2241569A1 (en) 2010-10-20
JP5456694B2 (ja) 2014-04-02
WO2009092278A1 (zh) 2009-07-30
AU2009207968A1 (en) 2009-07-30
US8318740B2 (en) 2012-11-27
EP2241569A4 (en) 2011-01-12
JP2011508750A (ja) 2011-03-17
US8962626B2 (en) 2015-02-24
MX2010007502A (es) 2010-10-15
CN101481380B (zh) 2012-10-17
RU2494103C2 (ru) 2013-09-27
RU2010128221A (ru) 2012-02-20
EP2241569B1 (en) 2012-05-23
US20130143887A1 (en) 2013-06-06
CA2711629C (en) 2017-10-24
KR20100117069A (ko) 2010-11-02
US20110009415A1 (en) 2011-01-13
AU2009207968B2 (en) 2014-04-24
BRPI0907228B1 (pt) 2021-08-03
CA2711629A1 (en) 2009-07-30
US9249154B2 (en) 2016-02-02

Similar Documents

Publication Publication Date Title
BRPI0910503A2 (pt) compostos, composições farmacêuticas e respectivos usos.
BRPI1009372A2 (pt) compostos, composição farmacêutica e respectivos usos
BRPI0908021A2 (pt) Composto, composição farmacêutica, e, usos do composto ou da composição farmacêutica
BRPI0918360A2 (pt) composto, composição farmacêutica e usos de um composto
BRPI1009324A2 (pt) compostos e/ou farmaceuticamente aceitáveis dos mesmos, composição farmacêutica e respectivos usos
BRPI0906962A2 (pt) Composto, e, composição farmacêutica
BRPI0906556A2 (pt) Composto, e, composição farmacêutica
BRPI1010772A2 (pt) composto,e, composição farmacêutica.
BRPI0918652A2 (pt) Composições farmacêuticas e métodos de libração relacionadas.
BRPI0820381A2 (pt) Formulações farmacêuticas
BRPI1010621A2 (pt) derivado de imidazoquinolinonas, sua composição farmacêutica e seu uso
BRPI0915897A2 (pt) compostos derivados triazóis, composições farmacêuticas e combinações dos mesmos e seus usos
DK3492069T3 (da) Farmaceutiske sammensætninger omfattende jern-oxy-hydroxid
BRPI0917681A2 (pt) Composto, e, composição farmacêutica
BRPI0822337A2 (pt) Folatos, composições e usos dos mesmos
BR112012004335A2 (pt) composto, composição farmacêutica, e, uso do composto.
DK2285357T3 (da) Farmaceutisk sammensætning omfattende brivaracetam
BR112012003842A2 (pt) composição farmacêutica, método de formulação e uso da mesma
BRPI0807078A2 (pt) Composto, e, formulação farmacêutica
BR112012031226A2 (pt) composto, uso do composto, composição farmacêutica, e uso de composição farmacêutica
BR112012003800A2 (pt) composição, peptídeo, e formulação farmacêutica.
BRPI0921654A2 (pt) formulação farmacêutica
DK2285413T3 (da) Farmaceutisk sammensætning
BR112012000831A2 (pt) compostos, composições farmacêuticas e métodos relacionados
BRPI0921313A2 (pt) composição farmaucêutica

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06A Notification to applicant to reply to the report for non-patentability or inadequacy of the application [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 07/01/2009, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.